Jocasta Neuroscience, Inc., a Scottsdale, Arizona-based biotechnology company developing treatments for cognitive impairment and neurodegenerative disease, announced on October 13, 2026, that it has entered into a research collaboration with Diamond Therapeutics Inc. to investigate three novel psychedelic-inspired compounds. The molecules were discovered through Diamond’s medicinal chemistry platform and are designed to reproduce selected aspects of psilocybin’s serotonin receptor interactions while avoiding activity associated with hallucinations.
Under the agreement, Jocasta will fund a preclinical research programme evaluating the compounds’ pharmacokinetics, behavioral effects and ability to improve cognitive performance. Following the research period, the company will have an option to secure exclusive rights to develop, manufacture and commercialize the candidates under a royalty-bearing license. The arrangement provides access to potential additional neurological treatments but does not represent an acquisition, a completed drug licensing transaction or the initiation of a human clinical trial.
The collaboration represents a strategic expansion for Jocasta, whose lead asset JN-0413 is based on the naturally occurring alpha-klotho protein. The company is preparing that programme for first-in-human testing in early 2027, creating a pipeline that could eventually include both protein-based and small-molecule approaches to cognitive dysfunction. However, the three Diamond compounds remain at the preclinical research stage, and neither company has disclosed human efficacy or safety results for them.
The central scientific question concerns whether researchers can separate potentially useful effects on neural signaling and plasticity from the altered perception associated with conventional psychedelic compounds. The concept has attracted considerable interest in neuroscience drug discovery, but translating receptor-level observations into reproducible improvements in cognition remains a substantial challenge. The Jocasta and Diamond agreement is designed to investigate that possibility rather than confirm that it has already been achieved.
How will Jocasta and Diamond evaluate the three psychedelic-inspired compounds?
The research programme will assess three new chemical entities identified through Diamond Therapeutics’ discovery platform. The compounds are intended to interact with the serotonin 5-HT2A receptor, a biological target associated with many of the characteristic effects of classical psychedelics. Jocasta will investigate whether their pharmacological properties support cognitive benefits without the behavioral changes typically associated with hallucinogenic activity.
The planned preclinical work includes pharmacokinetic studies to understand how the molecules are absorbed, distributed and eliminated. Behavioral investigations will evaluate whether they produce observable effects consistent with psychedelic-like activity. Cognitive assessments will examine whether treatment improves performance on experimental tasks relevant to learning or memory.
The companies intend to prioritize molecules demonstrating favorable cognitive effects without the hallucinogenic-like responses they are seeking to avoid. This creates an initial selection framework for further development, although the specific experimental models, dosing schedules and decision thresholds have not been publicly disclosed.
No compound has yet been identified as the final development candidate arising from the collaboration. The companies also have not announced completion of the planned preclinical studies or reported quantitative cognitive outcomes. The programme remains an exploratory effort to determine whether any of the three molecules merits more advanced investigation.
Why is the serotonin 5-HT2A receptor important for psychedelic-inspired drug development?
The serotonin 5-HT2A receptor is a G protein-coupled receptor involved in several aspects of neural signaling. Classical psychedelics such as psilocybin exert important parts of their pharmacological activity through interactions with this receptor. Its activation can influence neuronal communication, perception and other functions within the central nervous system.
Researchers are investigating whether receptor signaling can be directed toward biological effects that support neural plasticity without producing the full range of subjective psychedelic experiences. Neural plasticity refers to the ability of the nervous system to modify connections and activity patterns in response to experience or biological stimulation. These processes are relevant to learning and memory, although increasing a laboratory measure of plasticity does not automatically establish improved cognitive functioning.
Diamond’s programme draws on advances in medicinal chemistry and the understanding of signaling pathways downstream of individual receptors. Different molecules may interact with the same receptor while producing distinct patterns of intracellular signaling. This creates a possible route to developing compounds with different therapeutic and adverse-effect profiles despite engaging a shared molecular target.
However, the relationship between serotonin receptor signaling, neural plasticity and hallucinogenic activity is complex. Researchers have not established that all potentially beneficial effects of psychedelic compounds can be separated completely from their subjective effects in humans. The degree of separation may also depend on dose, tissue exposure and the specific pharmacological characteristics of each candidate.
The forthcoming preclinical work will therefore need to establish more than receptor binding. It must demonstrate whether the molecules influence relevant biological pathways, improve performance in appropriate experimental models and avoid unwanted behavioral effects at potentially useful exposures.
Can a medicine improve cognition without reproducing the psychedelic experience?
The commercial appeal of a non-hallucinogenic psychedelic-inspired medicine lies partly in the possibility of simpler treatment administration. Conventional psychedelic-assisted treatment models can require substantial clinical supervision because of acute changes in perception, emotion and behavior. A compound that retains useful pharmacological effects without producing those experiences might eventually support different dosing and monitoring strategies.
That possibility remains hypothetical for the molecules under investigation. The companies have not disclosed evidence showing that the candidates improve cognition in humans, and the ability to avoid hallucinogenic-like behavior in an animal model cannot definitively establish an absence of psychedelic effects in people.
There is also a distinction between reducing hallucinations and demonstrating a favorable overall safety profile. A compound may avoid certain behavioral effects while still producing unwanted cardiovascular, neurological or other physiological responses. Appropriate safety pharmacology, toxicology and exposure studies will therefore be necessary before clinical testing can be considered.
The intended neurological applications add further complexity. Cognitive impairment can arise from different biological processes, including neurodegeneration, vascular injury, inflammation and other disease-related changes. A medicine that produces an improvement in a laboratory memory task may not provide a clinically meaningful benefit across every disorder associated with cognitive decline.
For Jocasta and Diamond, the challenge is to demonstrate that their compounds have a sufficiently distinctive and reproducible biological profile to justify clinical development. The absence of hallucinations would be one potential characteristic, but efficacy and overall tolerability will ultimately determine their therapeutic value.
What are the financial terms of the Jocasta and Diamond Therapeutics agreement?
The collaboration provides Jocasta with an option-based route to future development rights rather than requiring an immediate acquisition of the three compounds. Jocasta will fund the agreed research activities and make an upfront payment to Diamond in the form of a convertible debenture. That instrument can be exchanged into preferred shares of Jocasta under the agreed terms.
Following completion of the research programme, Jocasta may exercise an option to obtain an exclusive, royalty-bearing license covering research, development, manufacturing and commercialization of the relevant compounds. If exercised, the license would entitle Diamond to further development and commercial milestone payments, together with tiered royalties on net sales. The companies have not disclosed the upfront debenture value, milestone amounts or royalty percentages.
The structure allows Jocasta to evaluate the assets before committing to a complete long-term licensing arrangement. This can be useful when molecules are at an early discovery stage and substantial uncertainty remains about their performance. It also provides Diamond with an opportunity to receive future financial consideration if the programme progresses.
However, the option does not guarantee that Jocasta will acquire the exclusive rights. An unsuccessful preclinical evaluation could result in no candidate being advanced, while successful results could lead to additional negotiations or contractual steps depending on the agreement. The announcement does not identify a fixed date by which the option must be exercised.
The financial impact is therefore difficult to quantify. Neither company has disclosed a transaction value sufficient to assess the investment required for the full research programme or any potential future commercial payments.
How does the research partnership complement Jocasta’s alpha-klotho treatment JN-0413?
Jocasta’s lead development programme, JN-0413, is based on a proprietary formulation of soluble alpha-klotho protein. Alpha-klotho is associated with biological processes involving aging and cellular function, and its levels can change over the lifespan. Research has investigated whether restoring or increasing alpha-klotho activity could influence cognitive performance and resilience to age-related neurological changes.
The company is developing JN-0413 as a subcutaneously administered candidate for cognitive impairment associated with neurodegenerative disease. It expects to begin first-in-human clinical testing in early 2027, subject to completion of the necessary development and regulatory steps. No clinical efficacy results for JN-0413 have yet been announced.
The new collaboration broadens the company’s scientific approach. Alpha-klotho treatment involves a protein-based intervention connected to aging biology, while the Diamond compounds are small molecules intended to modify serotonin receptor signaling. Their mechanisms are distinct, meaning positive findings from one programme would not establish efficacy for the other.
The two approaches may eventually address related clinical objectives, including improvement or preservation of cognitive performance. However, the companies have not announced plans to combine alpha-klotho treatment with the new psychedelic-inspired molecules. The present agreement concerns independent assessment of the small-molecule candidates.
For Jocasta, maintaining multiple mechanisms could provide pipeline diversification. It could also increase the capital and operational resources required as different programmes advance, making careful selection of development candidates commercially important.
What scientific evidence supports the alpha-klotho programme?
The scientific rationale for alpha-klotho has been investigated through animal experiments, human genetic research and observational studies. A study published in Nature Aging in 2023 reported that a single low-dose administration of alpha-klotho improved certain memory measures in aged rhesus macaques. The researchers observed an improvement in performance that persisted for at least two weeks after treatment.
The investigation also produced an important dose-related observation. Higher doses did not demonstrate the same cognitive improvements seen at the lower dose, suggesting that the relationship between exposure and performance may not be straightforward. The findings support additional research but do not establish an effective dose or therapeutic benefit in humans.
A separate study published in the European Journal of Neurology in 2024 examined cerebrospinal fluid alpha-klotho levels in 471 patients with Parkinson’s disease. Higher levels were associated with a later onset of cognitive impairment, with particular findings involving patients carrying certain GBA1 genetic variants. The study was observational and did not demonstrate that giving patients additional alpha-klotho would prevent cognitive decline.
These findings provide biological context for Jocasta’s lead programme. They do not demonstrate that JN-0413 is effective, and they cannot be used to validate the new serotonin-targeting compounds acquired through the Diamond research agreement.
The distinction between preclinical evidence, human association studies and randomized treatment trials remains essential. Each provides a different level of information about the potential usefulness of a therapeutic target. Jocasta must ultimately demonstrate clinical benefits through studies of its own investigational products.
Why is the expanded University of California San Francisco agreement important?
In August 2026, Jocasta announced a new licensing agreement with the University of California, San Francisco, to support development of alpha-klotho-based therapies. The agreement expanded and superseded an earlier intellectual property arrangement obtained through Unity Biotechnology. It strengthened the company’s rights around a programme connected with research conducted at UCSF.
The university’s work has contributed to understanding how alpha-klotho may affect synaptic activity and cognitive performance. Intellectual property covering those discoveries can provide a framework for developing proprietary formulations and pursuing clinical applications. However, holding exclusive development rights does not establish that an investigational medicine will achieve regulatory approval.
The agreement also reflects Jocasta’s strategy of building a pipeline through externally developed science. Rather than depending solely on internal discovery, the company is assembling technologies from academic institutions and other biotechnology organizations. The Diamond collaboration follows that approach by providing access to compounds developed through another company’s medicinal chemistry platform.
The two arrangements differ in maturity. JN-0413 is being prepared for human testing, while the Diamond compounds still require preclinical candidate evaluation. Their financial obligations and expected development timelines may therefore be substantially different.
What does Diamond Therapeutics’ existing psilocybin research contribute to the collaboration?
Diamond Therapeutics is a clinical-stage company with operations in Canada and the United States, developing treatments for neuropsychiatric conditions. Its research includes psilocybin-based approaches to generalized anxiety disorder and other conditions involving behavioral health. That work gives the company relevant expertise in serotonergic pharmacology and the development of novel compounds acting through serotonin-related pathways.
A separate Phase 2a study is investigating a low-dose psilocybin oral solution in patients with generalized anxiety disorder. The registered investigation involves daily administration and evaluates safety, tolerability and changes in anxiety symptoms. This programme is distinct from the three non-hallucinogenic psychedelic-inspired molecules being evaluated with Jocasta.
That distinction is important because clinical experience with psilocybin does not establish that newly designed non-hallucinogenic analogues will have comparable efficacy. Small structural differences can influence receptor activity, pharmacokinetics and biological effects. The new candidates must therefore undergo their own preclinical and, if justified, clinical testing.
Diamond’s medicinal chemistry expertise may help the partnership evaluate how different molecular structures influence signaling at the 5-HT2A receptor. However, the companies have not disclosed comparative potency data, receptor selectivity profiles or completed behavioral results for the three new compounds. Their pharmacological differentiation remains an objective of the research programme.
How could the collaboration influence Jocasta’s financing and development strategy?
Jocasta completed a $35 million Series A financing round in August 2025 to support development of its alpha-klotho programme. The financing was led by True Ventures and included participation from Moore Strategic Ventures, SC8 Investments, Glentura and other investors. At the time, the company expected the proceeds to support JN-0413 through initial clinical development, including planned single- and multiple-ascending-dose investigations.
The new collaboration introduces an additional research commitment beyond that lead programme. Jocasta will fund the evaluation of the Diamond compounds and provide an upfront convertible debenture. However, it has not disclosed how the research will affect the company’s cash runway or whether additional financing will be required.
The staged structure may help manage some of that uncertainty. Jocasta can evaluate the compounds before deciding whether to undertake the financial obligations associated with an exclusive commercial license. Nevertheless, successful preclinical findings would be expected to lead to further development costs rather than immediate commercial revenue.
Both companies are privately held, and the announcement does not include a public-market valuation, confirmed acquisition proposal or revenue forecast. Its significance is therefore primarily strategic and scientific. The eventual financial value will depend on whether one or more compounds progress sufficiently to support clinical testing and a viable development programme.
What must the three compounds demonstrate before human trials can begin?
The first milestone will be completion of the planned preclinical pharmacology and behavioral investigations. Researchers must establish whether the candidates engage their intended receptor pathways at appropriate exposures and whether any observed cognitive effects are reproducible. The assessment must also distinguish meaningful changes in cognitive performance from nonspecific effects on movement, arousal or behavior.
Additional studies would be required to characterize safety, metabolism, drug interactions and the potential consequences of repeated dosing. A molecule intended for chronic cognitive impairment may need a different safety and administration profile from a medicine used intermittently for a psychiatric condition. Long-term tolerability could therefore become a central development consideration.
The companies will also need to decide which disease population is most appropriate for clinical evaluation. Cognitive impairment associated with neurodegenerative disease is not a single uniform condition, and patients with Alzheimer’s disease, Parkinson’s disease or other disorders may have different underlying biological mechanisms. Selecting a defined indication will be essential for designing meaningful future studies.
If preclinical results support further development, Jocasta must determine whether to exercise its exclusive license option. That decision would likely depend on the quality of the pharmacological evidence, manufacturing feasibility, intellectual property and the capital needed for subsequent studies. Neither company has announced a candidate nomination date or a timetable for beginning human trials with the three compounds.
The October 2026 agreement expands Jocasta Neuroscience’s research pipeline by introducing three small molecules designed to investigate a difficult question in central nervous system drug development: whether potentially useful effects associated with psychedelic pharmacology can be retained without hallucinations. Diamond Therapeutics contributes medicinal chemistry and serotonin receptor expertise, while Jocasta provides research funding and a possible route toward future clinical development.
For now, the proposed benefits remain unproven, and there is no disclosed human efficacy or safety evidence for the new compounds. The partnership’s first meaningful test will be whether preclinical experiments demonstrate reproducible cognitive effects alongside an acceptable pharmacological and behavioral profile. A successful result could justify selecting a candidate for further development, but it would represent the beginning of a much longer process rather than confirmation of a new treatment for neurodegenerative disease.
